首页> 外文期刊>Neurochemical research >Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study.
【24h】

Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study.

机译:L型钙通道阻滞剂对氟哌啶醇引起的口面运动障碍的保护作用:一项行为,生化和神经化学研究。

获取原文
获取原文并翻译 | 示例
       

摘要

Haloperidol is a classical neuroleptic drug that is still in use and can lead to abnormal motor activity such as tardive dyskinesia (TD) following repeated administration. TD has no effective therapy yet. There is involvement of calcium in triggering the oxidative damage and excitotoxicity, both of which play central role in haloperidol-induced orofacial dyskinesia and associated alterations. The present study was carried out to investigate the protective effect of calcium channel blockers [verapamil (10 and 20 mg/kg), diltiazem (10 and 20 mg/kg), nifedipine (10 and 20 mg/kg) and nimodipine (10 and 20 mg/kg)] against haloperidol induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical alterations in rats. Chronic administration of haloperidol (1 mg/kg i.p., 21 days) resulted in a significant increase in orofacial dyskinetic movements and significant decrease in % retention, coupled with the marked increase in lipid peroxidation and superoxide anion generation where as significant decrease in non protein thiols and endogenous antioxidant enzyme (SOD and catalase) levels in rat brain striatum homogenates. All these deleterious effects of haloperidol were significantly attenuated by co-administration of different calcium channel blockers. Neurochemically, chronic administration of haloperidol resulted in significant decrease in levels of catecholamines (dopamine, serotonin) and their metabolites (HVA and HIAA) but increased turnover of dopamine and serotonin. Co-administration of most effective doses of verapamil, diltiazem, nifedipine and nimodipine significantly attenuated these neurochemical changes. Results of the present study indicate that haloperidol-induced calcium ion influx is involved in the pathogenesis of tardive dyskinesia and calcium channel blockers should be tested in clinical trials with nifedipine as the most promising one.
机译:氟哌啶醇是仍在使用的经典抗精神病药,反复给药后可导致异常的运动活动,如迟发性运动障碍(TD)。 TD尚无有效疗法。钙参与触发氧化损伤和兴奋性毒性,两者在氟哌啶醇引起的口面运动障碍及相关改变中起着重要作用。本研究旨在研究钙通道阻滞剂[维拉帕米(10和20 mg / kg),地尔硫卓(10和20 mg / kg),硝苯地平(10和20 mg / kg)和尼莫地平(10和20 mg / kg)]对抗氟哌啶醇引起的大鼠口面部运动障碍及相关的行为,生化和神经化学改变。氟哌啶醇的长期给药(1 mg / kg ip,21天)导致口面部运动障碍运动显着增加,%保留率显着降低,同时脂质过氧化和超氧阴离子生成显着增加,其中非蛋白质硫醇显着减少和大鼠脑纹状体匀浆中的内源性抗氧化酶(SOD和过氧化氢酶)水平。并用不同的钙通道阻滞剂可大大减轻氟哌啶醇的所有这些有害作用。从神经化学上讲,氟哌啶醇的长期给药导致儿茶酚胺(多巴胺,5-羟色胺)及其代谢产物(HVA和HIAA)的水平显着下降,但多巴胺和5-羟色胺的更新却增加了。最有效剂量的维拉帕米,地尔硫卓,硝苯地平和尼莫地平的共同给药显着减弱了这些神经化学变化。本研究的结果表明,氟哌啶醇诱导的钙离子流入参与迟发性运动障碍的发病机理,钙通道阻滞剂应在硝苯地平作为最有前途的临床试验中进行测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号